DRAPER, Utah, March 11, 2025 (GLOBE NEWSWIRE) -- The HealthEquity Community Foundation today announced the first recipients of grants from their inaugural grant cycle, and the application timeline for their next grant cycle. This marks a significant step forward in the Foundation’s aim of advancing its mission to support healthcare, financial literacy, mental health, and basic human needs in communities nationwide.
The HealthEquity Community Foundation’s next grant application cycle is now open. Grant submissions will be accepted through March 31. Eligible 501(c)(3) charitable organizations are encouraged to apply for funding to further their mission to support their own communities in the HealthEquity Community Foundation’s focus areas.
"We are inspired by the remarkable organizations dedicated to making a difference in their communities," said Dale Miller, president of the HealthEquity Community Foundation. "These grants are our first, tangible step as an organization to support real solutions that address critical needs around the country — from healthcare access to financial literacy and basic human needs."
After receiving many compelling applications, the Foundation has selected charitable non-profit organizations that are closely aligned with the Foundation’s mission and goals.
The 2024 grant recipients include:
More than $40,000 in grants have been awarded during this first round of giving to support charitable non-profit organizations in one or more of the following focus areas:
"At Soldiers' Angels, we are committed to ensuring that Veterans receive the critical assistance they need—whether it’s access to food, transportation to medical appointments, or essential services for those experiencing homelessness," said President and CEO of Soldiers' Angels, Amy Palmer. "This generous grant from HealthEquity Community will be instrumental in expanding our efforts and reaching even more Veterans in need. With their support, we can continue to stand by those who have served our country, providing the resources and care they deserve."
Many of these first-round grant recipients are also signature partners of the HealthEquity Purple with Purpose volunteer program, which provides opportunities for HealthEquity teammates to engage in in-person volunteer efforts, further deepening the company’s commitment to hands-on community involvement.
For more information on application details, and upcoming funding opportunities, please visit HealthEquity.com/community-foundation, or contact This email address is being protected from spambots. You need JavaScript enabled to view it..
About HealthEquity
HealthEquity and its subsidiaries administer HSAs and various other consumer-directed benefits for over 17 million accounts, working in close partnership with employers, benefits advisors, and health and retirement plan providers who share our unwavering commitment to our mission of saving and improving lives by empowering healthcare consumers. Through cutting-edge solutions, innovation, and a relentless focus on improving health outcomes, we empower individuals to take control of their healthcare journey while ultimately enhancing their overall well-being. Learn more about our “Purple service” and approach at www.healthequity.com.
Media Contact
Amy Cerny
This email address is being protected from spambots. You need JavaScript enabled to view it.
For the latest HealthEquity news visit our newsroom at https://www.healthequity.com/newsroom
Last Trade: | US$84.52 |
Daily Change: | 2.03 2.46 |
Daily Volume: | 934,108 |
Market Cap: | US$7.320B |
March 18, 2025 February 18, 2025 January 13, 2025 November 12, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load